

から第11回高精度外部照射研究会シンポジウム

- 3) T. Nishio, et al.: "Quality assurance of radiotherapy treatment planning system prior to stereotactic irradiation for lung tumor trial : Japan Clinical Oncology Group (JCOG) study", Radiotherapy and Oncology, ESTRO Amsterdam 2004 VOL.73/Supplement 1, S422.

新保宗史

- 1) Kanai, T, Fukumura, A, Shimbo, M, Nishio, T, et al.: Cross-calibration of ionization chambers in proton and carbon beams. Phys Med Biol 2004 ;49, 771-781.
- 2) 新保宗史：第三者機関による技術評価・品質管理の必要性 シンポジウム「体幹部定位治療に必要なQA」日本高精度放射線外部照射研究会2004/7/9
- 3) 新保宗史：放射線治療の品質管理と第三者機関について 日本放射線腫瘍学会将来計画委員会講演会「医学物理士問題ー精度管理とリスクマネジメント」 2004/10/29
- 4) 新保宗史、石倉聡、遠藤真広、池田恢、他：ガラス蛍光線量計を用いた郵送による線量調査 日本放射線腫瘍学会第17回学術大会 2004/11/18
- 5) 新保宗史：郵送線量計及び訪問による出力線量の全国調査 医療用標準線量研究会 平成16年12月10日
- 6) 新保宗史、遠藤真広：教育研修プログラムについて 池田班小班会議041223
- 7) 新保宗史：郵送・訪問による線量調査の現状報告 池田班小班会議041223
- 8) 新保宗史：絶対線量測定 of 品質管理プログラムと第三者機関の監査試案 (品質管理士講習会)2005年1月9日及び3月20日

福村明史

- 1) 福村明史、遠藤真広、他：治療用線量計の校正トレーサビリティとその不確かさ 医学物理、2004;24, suppl.3, 274-277.
- 2) 福村明史、遠藤真広、他：水吸収線量校正場の設定とルース型電離箱に対する校正定数比の評価 医学物理、2004;24, suppl.2, 198-199.
- 3) 福村明史、遠藤真広、他：新しい治療用線量計トレーサビリティと校正定数の不確かさ 医用標準線量、vol.9 No.1, 1-9, 2004
- 4) Fukumura, A, et al.: Proton beam dosimetry intercomparison with new Japanese protocol 医用標準線量、vol.9 No.1, 37-42, 2004
- 5) Kanai, T, Fukumura, A, Shimbo, M, Nishio, T, et al.: Cross-calibration of ionization chambers in proton and carbon beams. Phys Med Biol 2004 ;49, 771-781.
- 6) 早瀬尚文、遠藤真広、福村明史、他：国立弘前病院における過剰照射事故の原因および再発防止に関する調査報告書 日本医学放射線学会雑誌 第64巻5号365-375、2004他

加藤抱一

Sugiura T, Kato H, Tachimori Y, Yamaguchi H, et al.: Second primary carcinoma in the gastric tube constructed as an esophageal substitute after esophagectomy. J Amer Coll Surg 2002; 194:578-583.

Hishida T, Tachimori Y, Kato H, Yamaguchi H, et al.: Esophageal basaloid carcinoma with marked myoepithelial differentiation. Pathology International 2002; 52:313-317.

Yokoyama A, Kato H, Tachimori Y, et al.: Multiple cancers associated with esophageal and oropharyngolaryngeal squamous cell carcinoma and the Aldehyde Dehydrogenase-2 genotype in male Japanese drinkers. Cancer Epidemiol, Biomarkers & Prevention 2002; 895-900.

Yokoyama A, Kato H, et al.: Genetic polymorphisms of alcohol and aldehyde dehydrogenases and glutathione S-transferase M1 and drinking, smoking, and diet in Japanese men with esophageal squamous cell carcinoma. Carcinogenesis 2002; 1851-1859.

Igaki H, Kato H, Tachimori Y, et al.: Prognostic evaluation of patients with clinical T1 and T2 squamous cell carcinomas of the thoracic esophagus after 3-field lymph node dissection. Surgery 2003; 133:368-374.

Fang W, Kato H, Tachimori Y, et al.: Analysis of pulmonary complications after three-field lymph node dissection for esophageal cancer. Ann Thorac Surg 2003; 76:903-908.

Gotoh M, Kato H, et al.: Prediction of invasive activities in hepatocellular carcinomas with special reference to  $\alpha$ -fetoprotein and des- $\gamma$ -carboxyprothrombin. Jpn J Clin Oncol 2003;33:522-526.

Yokoyama T, Kato H, et al.: Alcohol flusing, alcohol and aldehyde dehydrogenase genotypes, and risk for esophageal squamous cell carcinoma in Japanese men. Cancer Epidemiol, Biomarkers & Prevention 2003;1227-1233.

Igaki H, Tachimori Y, Kato H.: Improved survival for patients with upper and/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection. Annals Surg 2004;239:483-490.

Yachida S, Tachimori Y, Kato H, et al.: Adenosquamous carcinoma of the esophagus. Clinicopathologic study of 18 cases. Oncology 2004;66: 218-225.

大山和一郎

1) 大山和一郎、他：EBMに基づいた口腔癌治療、東京都歯科医師会雑誌 2004;52(5) 313-319.

2) 上條朋之、大山和一郎、他：頸部食道癌の治療成績とその検討、頭頸部腫瘍 2004 ;30(1)61-66.

1. 学会発表

- 1) 林 隆一、大山和一郎、他 中咽頭側壁癌の治療成績、頭頸部腫瘍学会、2004.
- 2) 門田英輝、大山和一郎、他 頭頸部再建例における術後合併症の検討、頭頸部腫瘍学会、2004.
- 3) 清野洋一、大山和一郎、他 下咽頭後壁癌の頸部リンパ節転移に関する検討、頭頸部腫瘍学会、2004.

日月裕司

- 1: Narikiyo M, Tachimori Y, Kato H, et al.: Frequent and preferential infection of *Treponema denticola*, *Streptococcus mitis*, and *Streptococcus anginosus* in esophageal cancers. *Cancer Sci.* 2004;95:569-74.
- 2: Yachida S, Tachimori Y, Kato H, et al.: Adenosquamous carcinoma of the esophagus. Clinicopathologic study of 18 cases. *Oncology.* 2004;66:218-25.
- 3: Igaki H, Tachimori Y, Kato H, et al.: Improved survival for patients with upper and/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection. *Ann Surg.* 2004;239:483-90.
- 4: Igaki H, Kato H, Tachimori Y, et al.: Prognostic evaluation of patients with clinical T1 and T2 squamous cell carcinomas of the thoracic esophagus after 3-field lymph node dissection. *Surgery.* 2003;133:368-74.
- 5: Yokoyama A, Kato H, Tachimori Y, et al.: Multiple cancers associated with esophageal and oropharyngolaryngeal squamous cell carcinoma and the aldehyde dehydrogenase-2 genotype in male Japanese drinkers. *Cancer Epidemiol Biomarkers Prev.* 2002;11:895-900.
- 6: Hishida T, Tachimori Y, Kato H, Yamaguchi H, et al.: Esophageal basaloid carcinoma with marked myoepithelial differentiation. *Pathol Int.* 2002 Apr;52(4):313-7.
- 7: Sugiura T, Kato H, Tachimori Y, Yamaguchi H, et al.: Second primary carcinoma in the gastric tube constructed as an esophageal substitute after esophagectomy. *J Am Coll Surg.* 2002;194:578-83.

下山直人

- 1) Shimoyama N, et al.: An antisense oligonucleotide to the N-Methyl-D- Aspartate (NMDA) subunit, NMDAR1, attenuates NMDA-induced nociception, hyperalgesia and morphine tolerance, *J Pharmacol Experiment Therap* (in press)
- 2) Shimoyama N, et al.: Nebulized furosemide as a novel treatment for dypnea in terminal cancer patients, *J Pain Symptom Manag* 23(1): 73-76, 2002
- 3) Shimoyama, M., et al.: A mouse model of neuropathic cancer pain, *Pain* 99(2002)

175-183.

白尾国昭

- 1) Ohtsu A, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer; The Japan Clinical Oncology Group Study (JCOG9205). *J Clin Oncol.* 21(1): 54-59. 2003
- 2) Ohtsu A, Shirao K, et al. Phase II Study of Irinotecan in combination with 120-h infusion of 5-Fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703). *J Clin Oncol.* 22(1):28-32. 2003
- 3) Matsumura Y, Shirao K, et al. Phase I and Pharmacokinetic study of MCC-465 of doxorubicin(DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. *Annals of Oncology.* 15:517-525, 2004.
- 4) Shirao K, et al. Phase II study of oral S-1 for metastatic colorectal cancer. *Cancer.* 100: 2355-2361, 2004.
- 5) Sai K, Shirao K, et al. UGT1A1 Haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. *Clinical Pharmacology & Therapeutics.* 75(6):501-515, 2004.
- 6) Shirao K, et al. Comparison of the Efficacy, Toxicity, and Pharmacokinetics of a Uracil/ tegafur plus Oral Leucovorin Regimen between Japanese and American Patients with Advanced Colorectal Cancer: Joint USA and Japan Study of UFT / LV. *J Clin Oncol.* 22(17):3466-3474, 2004.
- 7) Yamao T, Shirao K, et al. Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites : a report from the gastrointestinal oncology study group of the Japan Clinical Oncology Group, JCOG 9603 trial. *Jpn J Clin Oncol.* 34(6):316-322, 2004.
- 8) Hosokawa A, Shirao K, et al. Long-term survivor of gastric small cell carcinoma. *Hepato-Gastroenterology* 51:1567-1570, 2004.
- 9) Hamaguchi T, Shirao K, et al. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. *Cancer Sci.* 95(7):608-613, 2004.
- 10) Goto A, Shirao K, et al. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. *Int J Clin Oncol.* 9:364-368, 2004.
- 11) Hosokawa A, Shirao K, et al. Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions

- of 5-fluorouracil. *Int J Clin Oncol*. 9:388-392, 2004.
- 12) Yonemori K, Shirao K, et al. Retrospective analysis of clinical results and predictors of response in chemo-naive advanced gastric cancer patients treated with S-1, an oral fluoropyrimidine derivative, as single-agent chemotherapy. *Gastric Cancer* ( In press)
  - 13) 白尾国昭、「がんの化学療法－現況と治療の実際－」 今月の治療、12(2):125-142,2004.
  - 14) 安井久晃、白尾国昭：「今後承認・発売される予定の新規抗がん剤」 月刊ナーシング、24(3):90-91,2004.
  - 15) 宇良敬、白尾国昭：がんの化学療法－知っておきたい標準的治療法「胃がん」 今月の治療、12(2):66-68, 2004.
  - 16) 白尾国昭、「大腸癌治療の New Strategy」 *Pharuma Medica*, 22(8):119-126, 2004.  
後藤歩、白尾国昭、「UFT－わが国で開発された経口抗癌剤の光と陰－」 *Mebio Oncology*, 1(3):28-34, 2004.

#### 篠田雅幸

- 1) 篠田雅幸：食道癌における salvage surgery. *臨外* 57(2): 191-198, 2002.
- 2) Kodaira, T, Shinoda M, et al.: Multivariate Analysis of Treatment Outcome in Patients With Esophageal Radiotherapy, *Am J Clin Oncol*, 26(4) 392-397,2003
- 3) 篠田雅幸、他：?. 食道癌, 放射線・化学療法の Knack&Pitfalls 5. 術後の補助療法、食道外科の要点と盲点 (文光堂)、348-350, 2003
- 4) 篠田雅幸、他：食道癌の外科治療, 臨床腫瘍学 第3版, 日本臨床腫瘍学会編 (癌と化学療法社)、598-613,2003
- 5) Ando, N, Shinoda, M, et al.: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group study-JCOG9204, *J Clin Oncol*, 21(24) 4592-4594,2003
- 6) 波戸岡俊三、篠田雅幸、他：食道癌周術期における intensive insulin therapy の有用性に関する検討、*日本消器外科学会雑誌*、37(10) :1595～1602,2004

#### 坪佐靖宏

- 1) Tsubosa Y, et al.: Effects of DOP-PCR amplification and labeling methods on the sensitivity and specificity of metaphase- and array-based comparative genomic hybridizations. *Cancer Genet Cytogenet*. (In press)
- 2) Mori K, Tsubosa Y, et al.: Highly specific marker genes for detecting minimal gastric cancer cells in cytology negative peritoneal washings. *Biochem Biophys Res Commun*. 2004, 23; 313(4): 931-7
- 3) Peng DF, Tsubosa Y, et al.: Alterations of chromosomal copy number during

progression of diffuse-type gastric carcinomas: metaphase- and array-based comparative genomic hybridization analyses of multiple samples from individual tumours. J Pathol. 2003, 201(3): 439-50

- 4) Shiomi H, Tsubosa Y, et al.: Cytogenetic heterogeneity and progression of esophageal squamous cell carcinoma. Cancer Genet Cytogenet. 2003, 147(1): 50-61

澤田俊夫

- 1) 澤田俊夫: JNN スペシャル「ナースのためのオンコロジー、これだけは知っておきたいがんの知識」澤田俊夫編、医学書院、東京、pp8-52、163-182、2003.7.15.
- 2) 澤田俊夫: 消化器内視鏡のトラブル防止マニュアル、鈴木博昭監修、幕内博康、熊井浩一郎、澤田俊夫、峯徹哉、藤盛孝博編集、日本メディカルセンター、東京、2004/10/30.
- 3) 澤田俊夫: 第3章 大腸・小腸、1 大腸ポリープ・ポリポーシス、腫瘍内視鏡学、長廻紘、大井至、坂本長逸、星原芳雄編、医学書院、東京、2004.10.15.、pp126-134